Properties of GLP-1 agonists and their use in type 2 diabetes

There are currently four glucagon-like peptide-1 (GLP-1) receptor agonists licensed for use in the treatment of type 2 diabetes in the UK: dulaglutide, exenatide, liraglutide and lixisenatide. Steve Chaplin gives an overview of their indications, mode of administration and adverse effects, and Professor Stephen Bain discusses their current place in therapy.

Properties of GLP-1 agonists and their use in type 2 diabetes

Add yours ↓
Web design and marketing agency Leamington Spa